Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing

Clinical-stage biotech secures incremental working capital amid filing delays and strategic pivot to core pain pipeline.

By The Northwire Desk — AI Analysis Jun 17, 2026 · 21:12 ZYUS · 0.495 ZYUS Life Sciences Corporation
Executive Summary
  • ZYUS Life Sciences closed the third tranche of its secured loan financing, raising CAD$200,000 in gross proceeds.
  • The cumulative secured loan balance now stands at CAD$645,000 against a total facility cap of CAD$2,000,000.
  • The loan carries a 12% annual interest rate, payable on maturity, with a six-month term.
  • Proceeds are designated for general working capital.
  • Insiders contributed CAD$100,000, marking a related-party transaction under MI 61-101.
  • The company expects to close additional tranches under the secured loan facility.
  • Regulatory compliance relies on TSX Venture Exchange approval and MI 61-101 exemptions.
Material Impact
  • The financing is a routine capital raise for a pre-revenue clinical-stage company.
  • CAD$200,000 is immaterial to overall operational needs but extends runway for working capital.
  • The stock has traded flat at $0.50 since late April 2026, indicating the market has already absorbed the capital raise narrative.
  • No unexpected valuation inflection or transformative event is present.
  • The financing mitigates near-term liquidity risk but does not alter the fundamental clinical or commercial trajectory.
ZYUS · Price
Company Overview
  • ZYUS Life Sciences Corporation is a clinical-stage biotechnology company focused on developing non-opioid pain therapeutics.
  • The company's lead product candidate is Trichomylin® softgel capsules, currently in Phase 2a testing for cancer-related pain.
  • The company recently announced a strategic realignment to discontinue international business development and wind down international legal entities to reduce overhead.
  • The focus is now exclusively on advancing the clinical pipeline and preparing for potential Phase 2b trials.
  • The company holds two U.S. patents related to cannabichromene (CBC) formulations for pain management.
Read the original news release →

More from ZYUS Life Sciences Corporation

Jun 24, 2026 · 20:46

Clinical-stage biotech secures incremental insider debt to fund working capital amid Phase 2a trial completion and filing delays.

Financings Jun 11, 2026 · 16:30

Streamlining operations and shedding non-core assets to preserve cash ahead of critical Phase 2a data readout amid regulatory filing delays.

Production / Operations May 28, 2026 · 00:11

ZYUS Slides into Limbo as Cease Trade Order Grinds Operations, While a Trickle of Insider Loans Can’t Mask a Race Against Time

Financings May 20, 2026 · 22:30

ZYUS Life Sciences Struggles with Regulatory Compliance Amidst Liquidity Crunch

Financings May 05, 2026 · 18:00

Patent Grant Offers IP Shield Amidst Liquidity Crunch and Regulatory Filing Delays

Other Apr 30, 2026 · 23:45

Zyus Faces Cease-Trade Risk as Filing Delays Shadow Clinical Progress

Other